Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Two gene therapies for sickle cell disease approved in US

U.S. regulators have approved two gene therapies for sickle cell disease

Laura Ungar
Friday 08 December 2023 16:57 GMT

Regulators on Friday approved two new gene therapies for sickle cell disease that doctors hope can cure the painful, inherited blood disorder that afflicts mostly Black people in the U.S.

The Food and Drug Administration said the one-time treatments can be used for patients 12 and older with severe forms of the disease. One, made by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first approved therapy based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. The other is made by Bluebird Bio and works differently.

Sickle cell disease is a rare, debilitating and life-threatening blood disorder with significant unmet need," the FDA's Dr. Nicole Verdun said in a statement announcing the approvals. “"We are excited to advance the field especially for individuals whose lives have been severely disrupted by the disease."

In the U.S., an estimated 100,000 people have the disease and about a fifth of them have the severe form. Sickle cell is most common among Black people and 1 in 365 Black babies are born with the disease nationally. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria, so the disease occurs more often in mosquito-prone regions such as Africa or in people whose ancestors lived in those places.

The disease affects hemoglobin, the protein in red blood cells that carries oxygen. A genetic mutation causes the cells to become sickle or crescent-shaped, which can block blood flow, causing excruciating pain, organ damage, stroke and other problems.

Current treatments include medications and blood transfusions. The only permanent solution is a bone marrow transplant, which must come from a closely matched donor without the disease and brings a risk of rejection.

The Vertex treatment was recently authorized in Britain and Bahrain and is under review elsewhere.

____

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in